Lenograstim
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: granocyte, lenograstim (genetical recombination), neutrogin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Lenograstim is a drug catalogued in DrugCentral. It was first approved by the PMDA in 1991. DrugCentral lists 1 molecular target, including CSF3R. Recorded indications include Chemotherapy-induced neutropenia, Refractory acute myeloid leukemia and Relapsed acute myeloid leukemia.
- Molecular targets: CSF3R (1 listed in DrugCentral).
- Indications: Chemotherapy-induced neutropenia, Refractory acute myeloid leukemia and Relapsed acute myeloid leukemia.
- ATC code: L03AA10 (Colony stimulating factors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Chemotherapy-induced neutropenia
- Refractory acute myeloid leukemia
- Relapsed acute myeloid leukemia
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Granulocyte colony-stimulating factor receptor | CSF3R | activator | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1993-11-01 | UK Medicines and Healthcare Products Regulatory Agency (MHRA) | — | Chugai Pharma UK Ltd | |
| 1991-12-01 | PMDA | — | CHUGAI PHARMACEUTICAL CO., LTD. |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L03AA10 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Febrile neutropenia | 832.1 |
| Acute graft versus host disease | 375.4 |
| Neutropenia | 365.9 |
| Mucosal inflammation | 258.2 |
| Thrombocytopenia | 214.5 |
| Sepsis | 196.5 |
| Bone marrow failure | 175.5 |
| Cytomegalovirus infection | 165.7 |
| Febrile bone marrow aplasia | 159.1 |
| Cystitis haemorrhagic | 126.9 |
| Chronic graft versus host disease | 126.1 |
| Human herpesvirus 6 infection | 124.2 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 135968-09-1 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Lenograstim used for?
DrugCentral lists the following indications for Lenograstim: Chemotherapy-induced neutropenia, Refractory acute myeloid leukemia and Relapsed acute myeloid leukemia.
How does Lenograstim work?
Its molecular targets in DrugCentral include CSF3R (activator).
When was Lenograstim first approved?
Lenograstim was first approved by the PMDA in 1991.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5167 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2109128 — compound record and bioactivity
- DrugBank DB13144 — drug record
- FDA UNII 6WS4C399GB — substance identity
- UniProt Q99062 (CSF3R) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.